DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins

Immunology and Cell Biology

Volumn 92, Issue 3, 2014, Pages 237-244

  De Andrade, Lucas Ferrari ^a,b   Smyth, Mark J ^a,c   Martinet, Ludovic ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

inflammation; nectin; NK; receptor; tumour

Indexed keywords

ANTIGEN; CD155 ANTIGEN; CD96 ANTIGEN; CELL ADHESION MOLECULE; DNAX ACCESSORY MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; NATURAL KILLER CELL RECEPTOR; NECTIN; NECTIN 2; PROTEIN; PROTEIN KINASE C; UNCLASSIFIED DRUG;

AUTOIMMUNITY; DENDRITIC CELL; HUMAN; IMMUNOSURVEILLANCE; NATURAL KILLER CELL; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; VIRUS INFECTION;

ANIMALS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL ADHESION MOLECULES; CELL ADHESION MOLECULES, NEURONAL; HUMANS; KILLER CELLS, NATURAL; MONITORING, IMMUNOLOGIC; NEOPLASMS;

EID: 84898969025     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2013.95     Document Type: Review

References (91)

1. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9: 503-510.
2. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9: 495-502.
3. Karre K. Natural killer cell recognition of missing self. Nat Immunol 2008; 9: 477-480.
4. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013; 31: 227-258.
5. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 2010; 115: 2167-2176.
6. Chan CJ, Andrews DM, Smyth MJ. Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer. Curr Opin Immunol 2012; 24: 246-251.
7. Sakisaka T, Takai Y. Biology and pathology of nectins and nectin-like molecules. Curr Opin Cell Biol 2004; 16: 513-521.
8. Chan CJ, Smyth MJ, Martinet L. Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death Differ 2014; 21: 5-14.
9. Burns GF, Triglia T, Werkmeister JA, Begley CG, Boyd AW. TLiSA1, a human T lineagespecific activation antigen involved in the differentiation of cytotoxic T lymphocytes and anomalous killer cells from their precursors. J Exp Med 1985; 161: 1063-1078.
10. Scott JL, Dunn SM, Jin B, Hillam AJ, Walton S, Berndt MC et al. Characterization of a novel membrane glycoprotein involved in platelet activation. J Biol Chem 1989; 264: 13475-13482.
11. Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 1996; 4: 573-581.
12. Tahara-Hanaoka S, Shibuya K, Onoda Y, Zhang H, Yamazaki S, Miyamoto A et al. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int Immunol 2004; 16: 533-538.
13. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003; 198: 557-567.
14. Tahara-Hanaoka S, Shibuya K, Kai H, Miyamoto A, Morikawa Y, Ohkochi N et al. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. Blood 2006; 107: 1491-1496.
15. Stanietsky N, Rovis TL, Glasner A, Seidel E, Tsukerman P, Yamin R et al. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur J Immunol 2013; 43: 2138-2150.
16. Shibuya A, Lanier LL, Phillips JH. Protein kinase C is involved in the regulation of both signaling and adhesion mediated by DNAX accessory molecule-1 receptor. J Immunol 1998; 161: 1671-1676.
17. Shibuya K, Lanier LL, Phillips JH, Ochs HD, Shimizu K, Nakayama E et al. Physical and functional association of LFA-1 with DNAM-1 adhesion molecule. Immunity 1999; 11: 615-623.
18. Ralston KJ, Hird SL, Zhang X, Scott JL, Jin B, Thorne RF et al. The LFA-1-associated molecule PTA-1 (CD226) on T cells forms a dynamic molecular complex with protein 4.1G and human discs large. J Biol Chem 2004; 279: 33816-33828.
19. Hara H, Wada T, Bakal C, Kozieradzki I, Suzuki S, Suzuki N et al. The MAGUK family protein CARD11 is essential for lymphocyte activation. Immunity 2003; 18: 763-775.
20. Hanada T, Lin L, Tibaldi EV, Reinherz EL, Chishti AH. GAKIN, a novel kinesin-like protein associates with the human homologue of the Drosophila discs large tumour suppressor in T lymphocytes. J Biol Chem 2000; 275: 28774-28784.
21. Bertin J, Wang L, Guo Y, Jacobson MD, Poyet JL, Srinivasula SM et al. CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane- associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B. J Biol Chem 2001; 276: 11877-11882.
22. Gross O, Grupp C, Steinberg C, Zimmermann S, Strasser D, Hannesschlager N et al. Multiple ITAM-coupled NK-cell receptors engage the Bcl10/Malt1 complex via Carma1 for NF-kappaB and MAPK activation to selectively control cytokine production. Blood 2008; 112: 2421-2428.
23. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006; 107: 159-166.
24. Kim HS, Das A, Gross CC, Bryceson YT, Long EO. Synergistic signals for natural cytotoxicity are required to overcome inhibition by c-Cbl ubiquitin ligase. Immunity 2010; 32: 175-186.
25. Kim HS, Long EO. Complementary phosphorylation sites in the adaptor protein SLP-76 promote synergistic activation of natural killer cells. Sci Signal 2012; 5: ra49.
26. Iguchi-Manaka A, Kai H, Yamashita Y, Shibata K, Tahara-Hanaoka S, Honda S et al. Accelerated tumour growth in mice deficient in DNAM-1 receptor. J Exp Med 2008; 205: 2959-2964.
27. Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001; 13: 459-463.
28. Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumours. J Exp Med 2008; 205: 2965-2973.
29. Chan CJ, Andrews DM, McLaughlin NM, Yagita H, Gilfillan S, Colonna M et al. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J Immunol 2010; 184: 902-911.
30. Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K, Ljunggren HG et al. Primary human tumour cells expressing CD155 impair tumour targeting by downregulating DNAM-1 on NK cells. J Immunol 2009; 183: 4921-4930.
31. El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW et al. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res 2007; 67: 8444-8449.
32. Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 2009; 119: 1251-1263.
33. Sanchez-Correa B, Gayoso I, Bergua JM, Casado JG, Morgado S, Solana R et al. Decreased expression of DNAM-1 on NK cells from acute myeloid leukaemia patients. Immunol Cell Biol 2012; 90: 109-115.
34. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011; 121: 3609-3622.
35. Castriconi R, Dondero A, Corrias MV, Lanino E, Pende D, Moretta L et al. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Research 2004; 64: 9180-9184.
36. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009; 113: 3503-3511.
37. Croxford JL, Tang ML, Pan MF, Huang CW, Kamran N, Phua CM et al. ATM-dependent spontaneous regression of early Emu-myc-induced murine B cell leukaemia depends on NK and T cells. Blood 2013; 121: 2512-2521.
38. Gasser S, Raulet DH. The DNA damage response arouses the immune system. Cancer Res 2006; 66: 3959-3962.
39. Seth S, Qiu Q, Danisch S, Maier MK, Braun A, Ravens I et al. Intranodal interaction with dendritic cells dynamically regulates surface expression of the costimulatory receptor CD226 protein on murine T cells. J Biol Chem 2011; 286: 39153-39163.
40. Welch MJ, Teijaro JR, Lewicki HA, Colonna M, Oldstone MB. CD8 T cell defect of TNF-alpha and IL-2 in DNAM-1 deficient mice delays clearance in vivo of a persistent virus infection. Virology 2012; 429: 163-170.
41. Magri G, Muntasell A, Romo N, Saez-Borderias A, Pende D, Geraghty DE et al. NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies. Blood 2011; 117: 848-856.
42. Prod'homme V, Sugrue DM, Stanton RJ, Nomoto A, Davies J, Rickards CR et al. Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112. J Gen Virol 2010; 91 (Pt 8), 2034-2039.
43. Kamran N, Takai Y, Miyoshi J, Biswas SK, Wong JS, Gasser S. Toll-like receptor ligands induce expression of the costimulatory molecule CD155 on antigen-presenting cells. PLoS One 2013; 8: e54406.
44. Vassena L, Giuliani E, Matusali G, Cohen E, Doria M. The human immunodeficiency virus type 1 Vpr protein upregulates PVR via activation of the ATR-mediated DNA damage response pathway. J Gen Virol (e-pub ahead of print 17 September 2013; doi:10.1099/vir.0.055541-0).
45. Tomasec P, Wang EC, Davison AJ, Vojtesek B, Armstrong M, Griffin C et al. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat Immunol 2005; 6: 181-188.
46. Prod'homme V, Sugrue DM, Stanton RJ, Nomoto A, Davies J, Rickards CR et al. Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112. J Gen Virol 2010; 91 (Pt 8), 2034-2039.
47. Matusali G, Potesta M, Santoni A, Cerboni C, Doria M. The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR. J Virol 2012; 86: 4496-4504.
48. Cella M, Presti R, Vermi W, Lavender K, Turnbull E, Ochsenbauer-Jambor C et al. Loss of DNAM-1 contributes to CD8\+ T-cell exhaustion in chronic HIV-1 infection. Eur J Immunol 2010; 40: 949-954.
49. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.
50. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
51. Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 2010; 115: 4293-4301.
52. Olson JA, Zeiser R, Beilhack A, Goldman JJ, Negrin RS. Tissue-specific homing and expansion of donor NK cells in allogeneic bone marrow transplantation. J Immunol 2009; 183: 3219-3228.
53. Zingoni A, Ardolino M, Santoni A, Cerboni C. NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses. Front Immunol 2012; 3: 408.
54. Sivori S, Carlomagno S, Falco M, Romeo E, Moretta L, Moretta A. Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood 2011; 117: 4284-4292.
55. Ardolino M, Zingoni A, Cerboni C, Cecere F, Soriani A, Iannitto ML et al. DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction. Blood 2011; 117: 4778-4786.
56. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007; 39: 857-864.
57. Qiu ZX, Zhang K, Qiu XS, Zhou M, Li WM. CD226 Gly307Ser association with multiple autoimmune diseases: a meta-analysis. Hum Immunol 2013; 74: 249-255.
58. Song G, Bae SC, Choi S, Ji J, Lee Y. Association between the CD226 rs763361 polymorphism and susceptibility to autoimmune diseases: a meta-analysis. Lupus 2012; 21: 1522-1530.
59. Du Y, Tian L, Shen LX, Wang F, Yu LK, Song Y et al. Association of the CD226 single nucleotide polymorphism with systemic lupus erythematosus in the Chinese Han population. Tissue Antigens 2011; 77: 65-67.
60. Maiti AK, Kim-Howard X, Viswanathan P, Guillen L, Qian X, Rojas-Villarraga A et al. Non-synonymous variant (Gly307Ser) in CD226 is associated with susceptibility to multiple autoimmune diseases. Rheumatology (Oxford) 2010; 49: 1239-1244.
61. Wieczorek S, Hoffjan S, Chan A, Rey L, Harper L, Fricke H et al. Novel association of the CD226 (DNAM-1) Gly307Ser polymorphism in Wegener's granulomatosis and confirmation for multiple sclerosis in German patients. Genes Immun 2009; 10: 591-595.
62. Verhoeven DH, de Hooge AS, Mooiman EC, Santos SJ, ten Dam MM, Gelderblom H et al. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Molecular Immunology 2008; 45: 3917-3925.
63. Shibuya K, Shirakawa J, Kameyama T, Honda S, Tahara-Hanaoka S, Miyamoto A et al. CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. J Exp Med 2003; 198: 1829-1839.
64. Dardalhon V, Schubart AS, Reddy J, Meyers JH, Monney L, Sabatos CA et al. CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J Immunol 2005; 175: 1558-1565.
65. Lozano E, Joller N, Cao Y, Kuchroo VK, Hafler DA. The CD226/CD155 Interaction Regulates the Proinflammatory (Th1/Th17)/Anti-Inflammatory (Th2) Balance in Humans. J Immunol 2013; 191: 3673-3680.
66. Flodstrom-Tullberg M, Bryceson YT, Shi FD, Hoglund P, Ljunggren HG. Natural killer cells in human autoimmunity. Curr Opin Immunol 2009; 21: 634-640.
67. Shi FD, Van Kaer L. Reciprocal regulation between natural killer cells and autoreactive T cells. Nat Rev Immunol 2006; 6: 751-760.
68. Fort MM, Leach MW, Rennick DM. A role for NK cells as regulators of CD4\+ T cells in a transfer model of colitis. J Immunol 1998; 161: 3256-3261.
69. Huang D, Shi FD, Jung S, Pien GC, Wang J, Salazar-Mather TP et al. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J 2006; 20: 896-905.
70. Matsumoto Y, Kohyama K, Aikawa Y, Shin T, Kawazoe Y, Suzuki Y et al. Role of natural killer cells and TCR gamma delta T cells in acute autoimmune encephalomyelitis. Eur J Immunol 1998; 28: 1681-1688.
71. Smeltz RB, Wolf NA, Swanborg RH. Inhibition of autoimmune T cell responses in the DA rat by bone marrow-derived NK cells in vitro: implications for autoimmunity. J Immunol 1999; 163: 1390-1397.
72. Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J ExpMed 1997; 186: 1677-1687.
73. Leavenworth JW, Wang X, Wenander CS, Spee P, Cantor H. Mobilization of natural killer cells inhibits development of collagen-induced arthritis. Proc Natl Acad Sci USA 2011; 108: 14584-14589.
74. Lu L, Ikizawa K, Hu D, Werneck MB, Wucherpfennig KW, Cantor H. Regulation of activated CD4\+ T cells by NK cells via the Qa-1-NKG2A inhibitory pathway. Immunity 2007; 26: 593-604.
75. Poirot L, Benoist C, Mathis D. Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity. Proc Natl Aca Sci USA 2004; 101: 8102-8107.
76. Sitrin J, Ring A, Garcia KC, Benoist C, Mathis D. Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2. J Exp Med 2013; 210: 1153-1165.
77. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Aca Sci USA 2003; 100: 9452-9457.
78. Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 2009; 10: 48-57.
79. Boles KS, Vermi W, Facchetti F, Fuchs A, Wilson TJ, Diacovo TG et al. A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur J Immunol 2009; 39: 695-703.
80. Levin SD, Taft DW, Brandt CS, Bucher C, Howard ED, Chadwick EM et al. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol 2011; 41: 902-915.
81. Joller N, Hafler JP, Brynedal B, Kassam N, Spoerl S, Levin SD et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol 2011; 186: 1338-1342.
82. Lozano E, Dominguez-Villar M, Kuchroo V, Hafler DA. The TIGIT/CD226 axis regulates human T cell function. J Immunol 2012; 188: 3869-3875.
83. Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Aca Sci USA 2009; 106: 17858-17863.
84. Liu S, Zhang H, Li M, Hu D, Li C, Ge B et al. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death and Differ 2013; 20: 456-464.
85. Wang PL, O'Farrell S, Clayberger C, Krensky AM. Identification and molecular cloning of tactile. A novel human T cell activation antigen that is a member of the Ig gene superfamily. J Immunol 1992; 148: 2600-2608.
86. Fuchs A, Cella M, Giurisato E, Shaw AS, Colonna M. Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J Immunol 2004; 172: 3994-3998.
87. Seth S, Maier MK, Qiu Q, Ravens I, Kremmer E, Forster R et al. The murine pan T cell marker CD96 is an adhesion receptor for CD155 and nectin-1. Biochem Biophys Res Comm 2007; 364: 959-965.
88. Meyer D, Seth S, Albrecht J, Maier MK, du Pasquier L, Ravens I et al. CD96 interaction with CD155 via its first Ig-like domain is modulated by alternative splicing or mutations in distal Ig-like domains. J Biol Chem 2009; 284: 2235-2244.
89. Chambers CA. The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol 2001; 22: 217-223.
90. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev 2008; 8: 59-73.
91. Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.